Fundraising FoxForesite Capital — 2022 Investments
8 investments dated 2022 · listed companies and verified rows first · show all
ArriVent BioPharma is a clinical-stage biopharmaceutical company focused on identifying, developing, and commercializing medicines for difficult-to-treat diseases, starting with cancers.
BiotechHealthtechMedical DevicesNewtown Square, US
Zhengbin (Bing) Yao(Executive Officer, Director)inBrent Rice(Chief Commercial Officer)in
BoardJason Zhang(Director)Cong Xu(Director)Stuart Lutzker(Director)
Co-investorsCatalio Capital Management, LPGeneral CatalystHBM Healthcare InvestmentsHBM PartnersHongShan Capital GroupLAV+4 more
.png)
FOLX is a digital healthcare platform designed for LGBTQIA+ adults, providing inclusive and affirming medical care.
Digital HealthHealthtechBoston, US
A.G. Breitenstein(Founder)inLena Ballantine(Executive Officer)inLiana M Guzman Weis(Executive Officer, Director)
BoardLynne Chou O'Keefe(Director)inMorgan Cheatham(Director)inLee Shapiro(Director)in
Co-investors7wire VenturesBessemer Venture PartnersCorewell Health VenturesDefine VenturesHabitat PartnersSeae Ventures+2 more
Co-investorsDecheng CapitalvenBio Partners
Karyopharm is a pharmaceutical company developing drugs based on its SINE (Selective Inhibitor of Nuclear Export) technology, with medicines targeting cancers including multiple myeloma and diffuse large B-cell lymphoma.
BiotechHealthtechNewton, US
Stuart Poulton(Executive Officer)inMichael Mano(Executive Officer)inReshma Rangwala(Executive Officer)inRichard Paulson(CEO)inStephen Mitchener(Executive Officer)inMichael Mason(Executive Officer)in
Co-investorsAvoro Capital AdvisorsHEALTHCARE ROYALTY PARTNERSRA Capital
Kriya provides working capital loans and business finance products to UK and European businesses, helping them manage cash flow, fund wholesale orders, and scale their buyer base.
FintechSaaS
Anil Stocker(Founder)inCharles Delingpole(Founder)Ilya Kondrashov(Founder)
Co-investorsHolland CapitalMouro CapitalNorthzoneBluebird VenturesJDRF T1D FundNarya Capital+3 more
Nested Therapeutics is a precision oncology company developing small-molecule cancer therapeutics by identifying overlooked driver mutations and novel binding pockets through a drug discovery platform combining genomics, computational biophysics, machine learning, and chemical biology.
AI & Machine LearningBiotechHealthtech
Arvin Dar(Co-founder & Board Observer)inKevan Shokat(Scientific Co-founder)Klaus Hoeflich(Co-founder & former Chief Scientific Officer)inDarrin Miles(Chief Executive Officer)inPhilip Komarnitsky(Chief Medical Officer)inTanja Weber(Chief Business Officer)in
Co-investorsVersant VenturesSixty Degree CapitalCowen Healthcare InvestmentsGoldman SachsSection 32
Developing ceftibuten-ledaborbactam etzadroxil, a clinical phase 3-ready oral beta-lactam/beta-lactamase inhibitor combination for complicated urinary tract infections.
BiotechMalvern, US
Christopher J. Burns(Executive Officer, Director)Daniel C. Pevear(Executive Officer)Michael Diem(Director)Vincent J. Milano(Director)Ezra Felker(Executive Officer)Shelley Chu(Director)
Co-investorsAMR Action FundBioAdvanceVersant Ventures
Other
Tracked investments with no reachable website or further public details — typically companies that wound down, renamed, or were absorbed.
TenSixteen Bio
Rows marked “SEC filing” are inferred from directors named on the company's SEC Form D — public regulatory data, not a portfolio list published by the firm.